Lilly takes back cancer drug with AurKa buy
Eli Lilly has unveiled a deal to buy AurKa Pharma, bringing back in-house experimental fisrt-in-class cancer drug AK-01.
Read More
Tag: Aurora kinase A inhibitor
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
